in the southeast to the Hardanger plateau in the west and the Halling mountains (1930 m above sea level) 5 in the northwest (Fig. 1 ).
| Patient material
Every Norwegian citizen has a unique personal identification 
| Incidence and prevalence
A Poisson distribution was assumed, and 95% CI was calculated for both prevalence and incidence. We calculated the crude point On prevalence day, 53.6% of the patient population were considered to have a relapsing-remitting disease phenotype, while 28.4%
| Statistical analysis

| RESULTS
| Prevalence
had a secondary progressive disease.
The age distribution of the prevalent MS population by disease phenotype. Number (N) and mean age with standard deviations are given for the patients in each MS phenotype 
| Incidence
The mean yearly incidence of MS between 2003 and 2013 was 11.8/100 000. After adjusting the data to the European standard population, the incidence fell slightly to 11.5/100 000. In the 5-year period between 2003 and 2007, the incidence in Buskerud was 10.2/100 000, and between 2008 and 2012, it was 13.1/100 000 (P<.01). The incidence was twice as high in women as in men (Fig. 3) .
Age specific incidence rates based on year of diagnosis are shown in Figure 4 .
The mean age of onset in relapsing-remitting MS was 33.6 years (median 33), and the mean age of onset in primary progressive MS was 43.9 (median 45) ( Table 1 ). The difference in age at onset between the two phenotypes was significant (P<.001).
| Diagnosis
The mean delay from onset to diagnosis of all our patients was 5.9 years, although the median was 3 years. One patient who had waited 50 years from onset before contacting a doctor was considered an outlier and was removed. However, over the last Adjusted to the European standard population.
In seven patients, initial disease course could not be defined retrospectively.
F I G U R E 4 Sex-standardized incidence rates with 95% confidence interval based on year of diagnosis stratified by age group per 100 000 
| DISCUSSION
Although Norway is one of the countries with the highest prevalence in the world, no nationwide studies of incidence have been performed. We found a point prevalence of 213.8/100 000, in line with the findings in the nationwide study 4 as well as the most recent local studies throughout Norway 11, 12 (Fig. 1) . A prevalence above 200/100 000 was also seen in the United Kingdom,
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Canada 14 and parts of Sweden. 15 An increase in prevalence is seen in most studies and may reflect improved diagnostic criteria and availability of healthcare services, but also increased survival in the MS population and the population as a whole. However, an increase in incidence, possibly due to changing environmental factors, may be an integral part of the answer, although our study did not specifically investigate this.
In 2012, a national incidence of 5.9/100 000 was postulated.
3
We found a relatively high incidence compared to this. We believe this is due to our method, which is arguably more precise, and date of acquisition, as Midgard's incidence is based on epidemiological studies on incidence from the 80s and 90s, while our numbers are Table 2 shows the most recent prevalences and incidences of Buskerud's neighbouring counties. A study on the prevalence and incidence of multiple sclerosis in the United Kingdom found a consistent downward trend in the incidence of MS between 1990 and 2010.
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However, Norway's neighbouring country Sweden found an increased incidence at 10.2 (2001-08) in a register-based incidence study. 22 In Oslo, the incidence rose from 3.6 (1972-76) to 8.7 (1992-96) 23 but then fell to 6.6 (2001-05). 24 The fall may, however, be due to the fairly recent high immigration rate in the Oslo area. MS incidence has also Norway have found both slightly lower and higher age of onset than ours, 11 with an average age of onset in the north of Norway being as high as 40 years.
12
We found a lengthy delay from onset to diagnosis of 5.9 years.
The median time from onset to diagnosis was 3 years. This is relatively high, though in accordance with other Norwegian studies. 12, 20, 23 However, when only including patients diagnosed in 2005 or after, the mean delay from onset to diagnosis is slightly reduced to 5.5 years (median 2). This difference is not significant (P=.19). The median time from onset to diagnosis in primary progressive disease was 2.5 years.
We focused on the most debilitating symptom at onset, regardless of other symptoms. Thus, a patient with paraplegia and urinary retention due to a medullary lesion would be categorized as having pyramidal symptoms at onset as this was considered the most debilitating
symptom. An Oslo study classifying MS symptoms similarly between 1972 and 1999 23 found that 30% of patients with MS had pyramidal symptoms at onset and 32% of patients had sensory symptoms.
In our study, 22% of all patients had pyramidal symptoms at onset, while 27% had sensory symptoms. Sensory symptoms at onset are associated with more benign disease progression. 26 Sensory symptoms were more common in patients with disease onset after 2005. | 417 A significant increase in cases with sensory compared to pyramidal symptoms at onset may again support the hypothesis that incidence is rising in part due to diagnosing more benign cases. The majority of patients with relapsing disease described sensory symptoms at onset, while patients with primary progressive disease defined pyramidal symptoms as the first symptom, in line with a more aggressive disease course in PP-MS.
T A B L E 2 Studies of prevalence and incidence in neighbouring counties
About 53.6% of our patients at the time of prevalence were thought to have a relapsing-remitting disease phenotype, and the mean age in this group was 45.9 vs 52.7 years in the Buskerud MS population as a whole. Thus, a large portion of our patients are in the middle of childbearing and working age, emphasizing the huge socio-economic impact this group represents if rendered disabled by relapses or progressive disease. 27, 28 Disease modifying drugs and other MS-related care are costly. One study by Svendsen et al. 29 found that the cost of patients with MS to the Norwegian society in 2002 was €439 million.
Direct economic costs accounted for 39%, and this was more than 7 times higher at EDSS (Expanded Disability Status Scale
30
)-levels 7-8 compared to levels 1-2. This does not even quantify the personal and social burden the disease has on the patient and their family. This highlights the need to perform updated, good-quality prevalence studies to be able to plan future health care.
In conclusion, our findings from Buskerud county are in line with other reports of a high prevalence of multiple sclerosis in Norway, but the incidence is high and may still be increasing. Further studies are needed to investigate the underlying causes of the increasing incidence.
